Continued Angiogenesis Suppression Following Progression on Bevacizumab in mCRC

Clinical Pearls

Paulo Marcelo Hoff, MD, PhD, FACP, University of S&atilde;o Paulo, Brazil, discusses continued angiogenesis suppression following progression on bevacizumab in metastatic colorectal cancer (mCRC). This study, which analyzes the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression &ge; 9 months versus < 9 months, was presented at the 2014 ASCO Annual Meeting.

• In mCRC, it is beneficial to continue to suppress angiogenesis after first progression, except in patients who had progressed rapidly on first-line therapy.
• Researchers set out to determine if the efficacy of the anti-angiogenic agent ziv-aflibercept was affected by the timing of progression on first-line therapy.
• At the start of the trial, 9 months was considered to be a reasonable cutoff between early and late progression.

<<<

View more from the 2014 ASCO Annual Meeting